Literature DB >> 15878095

Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.

John Yarnold1, Anita Ashton, Judith Bliss, Janis Homewood, Caroline Harper, Jane Hanson, Jo Haviland, Søren Bentzen, Roger Owen.   

Abstract

BACKGROUND AND
PURPOSE: Unlike squamous carcinomas, breast adenocarcinoma may be as sensitive to fraction size as late dose-limiting normal tissues. If so, fewer larger fractions would be as safe and effective as regimens based on 2.0 Gy fractions. The first step is to test the effects of radiotherapy fractions >2.0 Gy on late normal tissue responses in the breast after tumour excision and radiotherapy for early breast cancer. PATIENTS AND METHODS: One thousand four-hundred and ten women with T1-3 N0-1 M0 invasive breast cancer were randomised between 1986-98 into one of three radiotherapy regimens after local tumour excision of early stage breast cancer; 50 Gy in 25 fractions (F) vs two dose levels of a test schedule giving 39 or 42.9 Gy in 13 F over 5 weeks. Fraction sizes were 2.0, 3.0 and 3.3 Gy, respectively. The primary endpoint was late change in breast appearance compared to post-surgical appearance scored from annual photographs blinded to treatment allocation. Secondary endpoints included palpable breast induration (fibrosis) and ipsilateral tumour recurrence.
RESULTS: After a minimum 5-year follow up, the risk of scoring any change in breast appearance after 50 Gy/25 F, 39 Gy/13 F and 42.9 Gy/13 F was 39.6, 30.3 and 45.7%, from which an alpha/beta value of 3.6 Gy (95% CI 1.8-5.4) is estimated. The alpha/beta value for palpable breast induration was 3.1 Gy (95% CI 1.8-4.4).
CONCLUSIONS: An alpha/beta value of around 3 Gy for late normal tissue changes in the breast is derived from the estimated equivalence of 41.6 Gy in 13 fractions and 50 Gy in 25 fractions over 5 weeks, in line with trial predictions.

Entities:  

Mesh:

Year:  2005        PMID: 15878095     DOI: 10.1016/j.radonc.2005.01.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  110 in total

Review 1.  Hypofractionated radiation therapy in the treatment of early-stage breast cancer.

Authors:  Gary M Freedman
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Radiotherapy. Hypofractionation for breast cancer--clinical implications.

Authors:  Bruce G Haffty
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

3.  A planning comparison of 7 irradiation options allowed in RTOG 1005 for early-stage breast cancer.

Authors:  Guang-Pei Chen; Feng Liu; Julia White; Frank A Vicini; Gary M Freedman; Douglas W Arthur; X Allen Li
Journal:  Med Dosim       Date:  2014-08-22       Impact factor: 1.482

4.  Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation-induced dermatitis in breast cancer patients.

Authors:  T Hijal; A A Al Hamad; T Niazi; K Sultanem; B Bahoric; T Vuong; T Muanza
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

5.  The media and cancer survival.

Authors:  Heather Goodare
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

6.  Are Three Weeks of Whole-Breast Radiotherapy as Good as Five Weeks in Early Breast Cancer? - 10 Year Follow-Up in the Canadian Trial of Hypofractionated Radiation Therapy.

Authors: 
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

7.  5-Year Update of a Multi-Institution, Prospective Phase 2 Hypofractionated Postmastectomy Radiation Therapy Trial.

Authors:  Matthew M Poppe; Zeinab A Yehia; Christopher Baker; Sharad Goyal; Deborah Toppmeyer; Laurie Kirstein; Chunxia Chen; D F Moore; Bruce G Haffty; Atif J Khan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-11       Impact factor: 7.038

8.  Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.

Authors:  Sriram Venigalla; David M Guttmann; Varsha Jain; Sonam Sharma; Gary M Freedman; Jacob E Shabason
Journal:  Clin Breast Cancer       Date:  2018-02-21       Impact factor: 3.225

9.  Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.

Authors:  Justin E Bekelman; Gosia Sylwestrzak; John Barron; Jinan Liu; Andrew J Epstein; Gary Freedman; Jennifer Malin; Ezekiel J Emanuel
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

Review 10.  Hypofractionated radiation treatment in the management of breast cancer.

Authors:  Apar Gupta; Nisha Ohri; Bruce G Haffty
Journal:  Expert Rev Anticancer Ther       Date:  2018-06-26       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.